These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23151945)

  • 21. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
    Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
    Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of Metastases via Myeloid CD39 and NK Cell Effector Function.
    Yan J; Li XY; Roman Aguilera A; Xiao C; Jacoberger-Foissac C; Nowlan B; Robson SC; Beers C; Moesta AK; Geetha N; Teng MWL; Smyth MJ
    Cancer Immunol Res; 2020 Mar; 8(3):356-367. PubMed ID: 31992567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
    Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
    J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
    Honsik CJ; Jung G; Reisfeld RA
    Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining Immunocytokine and
    Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
    Front Immunol; 2021; 12():668307. PubMed ID: 34489927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.
    Shi Y; Felder MA; Sondel PM; Rakhmilevich AL
    Mol Immunol; 2015 Aug; 66(2):208-15. PubMed ID: 25829245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
    Tarek N; Le Luduec JB; Gallagher MM; Zheng J; Venstrom JM; Chamberlain E; Modak S; Heller G; Dupont B; Cheung NK; Hsu KC
    J Clin Invest; 2012 Sep; 122(9):3260-70. PubMed ID: 22863621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
    Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
    Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
    Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.
    Vicari AP; Chiodoni C; Vaure C; Aït-Yahia S; Dercamp C; Matsos F; Reynard O; Taverne C; Merle P; Colombo MP; O'Garra A; Trinchieri G; Caux C
    J Exp Med; 2002 Aug; 196(4):541-9. PubMed ID: 12186845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
    Lin CC; Shen YC; Chuang CK; Liao SK
    Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
    Van De Voort TJ; Felder MA; Yang RK; Sondel PM; Rakhmilevich AL
    J Immunother; 2013 Jan; 36(1):29-40. PubMed ID: 23211623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.